Molbio Diagnostics Limited
NSE: MOLBIO · Medical Equipment & Supplies
Snapshot
Unlock Molbio Diagnostics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Molbio Diagnostics Limited is an innovation-led diagnostics company specialising in accessible, accurate, and affordable molecular testing. The company designs, develops, and manufactures decentralized, point-of-care medical devices and disease-specific consumables, anchored by its flagship Truenat real-time PCR platform.
Vertical mix
- NaN%
Business Model
The company operates a recurring revenue model driven by the sale of disease-specific, single-use micro-PCR test kits alongside its portable Truenat testing devices. It maintains a broad test menu covering numerous infectious diseases, with ongoing expansion into oncology and non-communicable diseases.
- Truenat Devices Installed:12,500+
- Test Kits Sold (FY26):17.56 million
Management Commentary
Management focuses on expanding decentralized point-of-care diagnostics globally and broadening its assay portfolio to address a wider range of health conditions. The company continues to scale its installed device base across more than 90 countries.
Growth Outlook
Growth is expected to be driven by the expansion of the test menu into oncology and non-communicable diseases, alongside deeper penetration in global markets. The recurring demand for single-use test kits provides a steady platform for future volume growth.
- Total Income (FY26):1,455 crore rupees
- EBITDA (FY26):328 crore rupees
- Profit After Tax (FY26):164 crore rupees
Key Risks
- Regulatory and Approval Risks. Delays in obtaining or renewing regulatory approvals for new assays and medical devices in international markets could impact expansion plans.
- Geographic Concentration. A significant portion of revenues relies on public health programmes and tender-based procurement, which can be subject to policy shifts and budgetary constraints.
- Technological Obsolescence. Rapid advancements in diagnostics and point-of-care testing require continuous R&D investment to maintain competitive advantage against emerging alternatives.
Start your research today
Unlock AI insights, financials, peers and live data on Molbio Diagnostics Limited and 5,000+ companies — free.
Peers · Medical Equipment & Supplies
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Molbio Diagnostics LimitedMOLBIO | ₹15,133 Cr | — | — | — | 19.0% | — | — | — |
Poly Medicure Ltd.POLYMED | ₹17,501 Cr | 52.69 | 31.06 | 18.3% | 28.7% | 10.7% | 14.2% | -16.0% |
Fischer Medical Ventures LimitedFISCHER | ₹2,272 Cr | 13.94 | 41.34 | 196.0% | 15.4% | 7.7% | 12.8% | -68.9% |
Tarsons ProductsTARSONS | ₹1,785 Cr | 157.61 | 14.68 | 10.6% | 33.1% | 1.8% | 4.5% | +6.6% |
Laxmi DentalLAXMIDENTL | ₹1,072 Cr | 34.25 | 19.35 | — | 19.2% | 13.7% | 13.3% | -40.8% |
Hemant Surgical Industries LimitedHSIL | ₹894 Cr | — | — | — | 10.0% | — | — | +91.5% |
As of Mar 2026
Financials
Molbio Diagnostics Limited
NSE: MOLBIO · Medical Equipment & Supplies
Snapshot
Unlock Molbio Diagnostics Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Molbio Diagnostics Limited is an innovation-led diagnostics company specialising in accessible, accurate, and affordable molecular testing. The company designs, develops, and manufactures decentralized, point-of-care medical devices and disease-specific consumables, anchored by its flagship Truenat real-time PCR platform.
Vertical mix
- NaN%
Business Model
The company operates a recurring revenue model driven by the sale of disease-specific, single-use micro-PCR test kits alongside its portable Truenat testing devices. It maintains a broad test menu covering numerous infectious diseases, with ongoing expansion into oncology and non-communicable diseases.
- Truenat Devices Installed:12,500+
- Test Kits Sold (FY26):17.56 million
Management Commentary
Management focuses on expanding decentralized point-of-care diagnostics globally and broadening its assay portfolio to address a wider range of health conditions. The company continues to scale its installed device base across more than 90 countries.
Growth Outlook
Growth is expected to be driven by the expansion of the test menu into oncology and non-communicable diseases, alongside deeper penetration in global markets. The recurring demand for single-use test kits provides a steady platform for future volume growth.
- Total Income (FY26):1,455 crore rupees
- EBITDA (FY26):328 crore rupees
- Profit After Tax (FY26):164 crore rupees
Key Risks
- Regulatory and Approval Risks. Delays in obtaining or renewing regulatory approvals for new assays and medical devices in international markets could impact expansion plans.
- Geographic Concentration. A significant portion of revenues relies on public health programmes and tender-based procurement, which can be subject to policy shifts and budgetary constraints.
- Technological Obsolescence. Rapid advancements in diagnostics and point-of-care testing require continuous R&D investment to maintain competitive advantage against emerging alternatives.
Start your research today
Unlock AI insights, financials, peers and live data on Molbio Diagnostics Limited and 5,000+ companies — free.
Peers · Medical Equipment & Supplies
As of Mar 2026